The synergistic and opposing roles of ω-fatty acid hydroxylase (CYP4A11) and ω-1 fatty acid hydroxylase (CYP2E1) in chronic liver disease
Main Article Content
Abstract
Abstract
Cytochrome P450 fatty acid hydroxylase consists of members of the CYP4 family that ω-hydroxylate fatty acids and the CYP2E1 that ω-1 hydroxylates fatty acids. Although ω and ω-1 hydroxylation of fatty acids have been thought to play a minor role in fatty acid metabolism (less than 20%), it plays a vital role in excess liver fatty acids overload seen in fasting, diabetes, metabolic disorder, and over-consumption of alcohol and high-fat diet. This pathway provides anabolic metabolites for gluconeogenesis, succinate, and acetate for lipogenesis. The CYP4A and CYP2E1 genes are activated in fasting and several metabolic disorders, suggesting a synergistic role in preventing fatty acid-induced lipotoxicity with the consequence of increased liver cholesterol and lipogenesis leading to increased Lipid Droplet (LD) deposition. During the progression of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), activation of Phospholipase A2 (PLA2) releases arachidonic acid that CYP4A11 and CYP2E1 P450s metabolize to produce 20-hydroxyeicosatetraenoic acid (20-HETE) and 19-HETE, respectively. These metabolites have opposing roles in the progression of MASLD and chronic liver disease (CLD). This report discusses the synergistic role of the CYP4A and CYP2E1 P450s in the metabolism of saturated and unsaturated fatty acids and their opposite physiological role in the metabolism of Arachidonic Acid (AA). We finally discuss the role of ethanol in disrupting the synergistic and opposing roles of the CYP4A and CYP2E1 genes in MASLD and CLD.
Downloads
Article Details
Copyright (c) 2024 Hardwick JP, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing and protecting the author rights is the central aim and core of the publishing business. Peertechz dedicates itself in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. Peertechz licensing terms are formulated to facilitate reuse of the manuscripts published in journals to take maximum advantage of Open Access publication and for the purpose of disseminating knowledge.
We support 'libre' open access, which defines Open Access in true terms as free of charge online access along with usage rights. The usage rights are granted through the use of specific Creative Commons license.
Peertechz accomplice with- [CC BY 4.0]
Explanation
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
With this license, the authors are allowed that after publishing with Peertechz, they can share their research by posting a free draft copy of their article to any repository or website.
'CC BY' license observance:
|
License Name |
Permission to read and download |
Permission to display in a repository |
Permission to translate |
Commercial uses of manuscript |
|
CC BY 4.0 |
Yes |
Yes |
Yes |
Yes |
The authors please note that Creative Commons license is focused on making creative works available for discovery and reuse. Creative Commons licenses provide an alternative to standard copyrights, allowing authors to specify ways that their works can be used without having to grant permission for each individual request. Others who want to reserve all of their rights under copyright law should not use CC licenses.
Hardwick JP. Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases. Biochem Pharmacol. 2008;75(12):2263-75. Available from: https://doi.org/10.1016/j.bcp.2008.03.004
Garcia V, Shkolnik B, Milhau L, Falck JR, Schwartzman ML. 20-HETE activates the transcription of angiotensin-converting enzyme via nuclear factor-kappaB translocation and promoter binding. J Pharmacol Exp Ther. 2016;356(3):525-33. Available from: https://doi.org/10.1124/jpet.115.229377
Garcia V, Gilani A, Shkolnik B, Pandey V, Zhang FF, Dakarapu R, et al. 20-HETE signals through G-protein-coupled receptor GPR75 (Gq) to affect vascular function and trigger hypertension. Circ Res. 2017;120(11):1776-88. Available from: https://doi.org/10.1161/circresaha.116.310525
Li B, Ma Y, Tan L, Ren H, Wu L, Su Q, et al. 20-Hydroxytetraenoic acid induces hepatic fibrosis via the TGF-beta1/Smad3 signaling pathway. Toxicol Lett. 2023;373:1-12. Available from: https://doi.org/10.1016/j.toxlet.2022.11.001
Akbari P, Gilani A, Sosina O, Kosmicki JA, Khrimian L, Fang YY, et al. Sequencing of 640,000 exomes identifies GPR75 variants associated with protection from obesity. Science. 2021;373(6558). Available from: https://doi.org/10.1126/science.abf8683
Leeson-Payne C, Iyinikkel J, Malcolm C, Lam BYH, Sommer N, Dowsett GK, et al. Loss of GPR75 protects against non-alcoholic fatty liver disease and body fat accumulation. Cell Metab. 2024;36(6):1076-87.e4. Available from: https://doi.org/10.1016/j.cmet.2024.03.016
Yi X, Wu L, Liao D, Wang C, Zhang B. Interactions among CYP2C8, EPHX2, and CYP4A11 variants and CYP plasma metabolite levels in ischemic stroke. J Atheroscler Thromb. 2016;23(11):1286-93. Available from: https://doi.org/10.5551/jat.35279
Zhang X, Li S, Zhou Y, Su W, Ruan X, Wang B, et al. Ablation of cytochrome P450 omega-hydroxylase 4A14 gene attenuates hepatic steatosis and fibrosis. Proc Natl Acad Sci U S A. 2017;114(12):3181-5. Available from: https://doi.org/10.1073/pnas.1700172114
Holla VR, Adas F, Imig JD, Zhao X, Price EJ Jr, Olsen N, et al. Alterations in the regulation of androgen-sensitive Cyp4a monooxygenases cause hypertension. Proc Natl Acad Sci U S A. 2001;98(9):5211-6. Available from: https://doi.org/10.1073/pnas.081627898
Laethem RM, Balazy M, Falck JR, Laethem CL, Koop DR. Formation of 19(S)-, 19(R)-, and 18(R)-hydroxyeicosatetraenoic acids by alcohol-inducible cytochrome P450 2E1. J Biol Chem. 1993;268(18):12912-8. Available from: https://pubmed.ncbi.nlm.nih.gov/8509425/
Tunaru S, Chennupati R, Nursing RM, Offermanns S. Arachidonic acid metabolite 19(S)-HETE induces vasorelaxation and platelet inhibition by activating prostacyclin (IP) receptor. PLoS One. 2016;11(10). Available from: https://doi.org/10.1371/journal.pone.0163633
Vinokurova M, Lopes-Pires ME, Cypaite N, Shala F, Armstrong PC, Ahmetaj-Shala B, et al. Widening the prostacyclin paradigm: tissue fibroblasts are a critical site of production and antithrombotic protection. Arterioscler Thromb Vasc Biol. 2024;44(2):271-86. Available from: https://doi.org/10.1161/atvbaha.123.318923
Osmundsen H, Bremer J, Pedersen JI. Metabolic aspects of peroxisomal beta-oxidation. Biochim Biophys Acta. 1991;1085(2):141-58. Available from: https://doi.org/10.1016/0005-2760(91)90089-z
Vamecq J, Draye JP. Peroxisomal and mitochondrial beta-oxidation of monocarboxylyl-CoA, omega-hydroxymonocarboxylyl-CoA and dicarboxylyl-CoA esters in tissues from untreated and clofibrate-treated rats. J Biochem. 1989;106(2):216-22. Available from: https://doi.org/10.1093/oxfordjournals.jbchem.a122835
Vamecq J, Draye JP. Pathophysiology of peroxisomal beta-oxidation. Essays Biochem. 1989;24:115-225. Available from: https://pubmed.ncbi.nlm.nih.gov/2676523/
Wada F, Usami M. Studies on fatty acid omega-oxidation: antiketogenic effect and gluconeogenicity of dicarboxylic acids. Biochim Biophys Acta. 1977;487(3):361-8. Available from: https://pubmed.ncbi.nlm.nih.gov/861239/
Adas F, Salaun JP, Berthou F, Picart D, Simon B, Amet Y. Requirement for omega and (omega-1)-hydroxylations of fatty acids by human cytochromes P450 2E1 and 4A11. J Lipid Res. 1999;40(10):1990-7. Available from: https://pubmed.ncbi.nlm.nih.gov/10553002/
Rizzo WB. Fatty aldehyde and fatty alcohol metabolism: review and importance for epidermal structure and function. Biochim Biophys Acta. 2014;1841(3):377-89. Available from: https://doi.org/10.1016/j.bbalip.2013.09.001
Hall AM, Wiczer BM, Herrmann T, Stremmel W, Bernlohr DA. Enzymatic properties of purified murine fatty acid transport protein 4 and analysis of acyl-CoA synthetase activities in tissues from FATP4 null mice. J Biol Chem. 2005;280(13):11948-54. Available from: https://doi.org/10.1074/jbc.m412629200
Lu Y, George J. Interaction between fatty acid oxidation and ethanol metabolism in liver. Am J Physiol Gastrointest Liver Physiol. 2024;326(5). Available from: https://doi.org/10.1152/ajpgi.00281.2023
Ranea-Robles P, Chen H, Stauffer B, Yu C, Bhattacharya D, Friedman SL, et al. The peroxisomal transporter ABCD3 plays a major role in hepatic dicarboxylic fatty acid metabolism and lipid homeostasis. J Inherit Metab Dis. 2021;44:1419-1433. Available from: https://doi.org/10.1002/jimd.12440
Ferdinandusse S, Denis S, Van Roermund CW, Wanders RJ, Dacremont G. Identification of the peroxisomal beta-oxidation enzymes involved in the degradation of long-chain dicarboxylic acids. J Lipid Res. 2004;45:1104-1111. Available from: https://doi.org/10.1194/jlr.m300512-jlr200
Bergseth S, Hokland BM, Bremer J. Metabolism of dicarboxylic acids in vivo and in the perfused kidney of the rat. Biochim Biophys Acta. 1988;961:103-109. Available from: https://doi.org/10.1016/0005-2760(88)90135-x
Suzuki H, Yamada J, Watanabe T, Suga T. Compartmentation of dicarboxylic acid beta-oxidation in rat liver: importance of peroxisomes in the metabolism of dicarboxylic acids. Biochim Biophys Acta. 1989;990:25-30. Available from: https://doi.org/10.1016/s0304-4165(89)80007-8
Tserng KY, Griffin RL, Kerr DS. Distinction of dicarboxylic aciduria due to medium-chain triglyceride feeding from that due to abnormal fatty acid oxidation and fasting in children. Metabolism. 1996;45:162-167. Available from: https://doi.org/10.1016/s0026-0495(96)90047-5
Jin Z, Bian F, Tomcik K, Kelleher JK, Zhang GF, Brunengraber H. Compartmentation of metabolism of the C12-, C9-, and C5-n-dicarboxylates in rat liver, investigated by mass isotopomer analysis: anaplerosis from dodecanedioate. J Biol Chem. 2015;290:18671-18677. Available from: https://doi.org/10.1074/jbc.m115.651737
Hunt MC, Rautanen A, Westin MA, Svensson LT, Alexson SE. Analysis of the mouse and human acyl-CoA thioesterase (ACOT) gene clusters shows that convergent, functional evolution results in a reduced number of human peroxisomal ACOTs. FASEB J. 2006;20:1855-1864. Available from: https://doi.org/10.1096/fj.06-6042com
Westin MA, Hunt MC, Alexson SE. The identification of a succinyl-CoA thioesterase suggests a novel pathway for succinate production in peroxisomes. J Biol Chem. 2005;280:38125-38132. Available from: https://doi.org/10.1074/jbc.m508479200
Mortensen PB. The possible antiketogenic and gluconeogenic effect of the omega-oxidation of fatty acids in rats. Biochim Biophys Acta. 1980;620:177-185. Available from: https://doi.org/10.1016/0005-2760(80)90199-x
Leighton F, Bergseth S, Rortveit T, Christiansen EN, Bremer J. Free acetate production by rat hepatocytes during peroxisomal fatty acid and dicarboxylic acid oxidation. J Biol Chem. 1989;264:10347-10350. Available from: https://pubmed.ncbi.nlm.nih.gov/2732225/
Wang Y, Zhang L, Gai Y, He H, Qiu P, Li P. Identification of key biomarkers in hepatocellular carcinoma induced by non-alcoholic steatohepatitis or metabolic syndrome via integrated bioinformatics analysis. Cell Mol Biol (Noisy-le-Grand). 2023;69:174-180. Available from: https://doi.org/10.14715/cmb/2023.69.7.28
Leahy C, Osborne N, Shirota L, Rote P, Lee YK, Song BJ, et al. The fatty acid omega hydroxylase genes (CYP4 family) in the progression of metabolic dysfunction-associated steatotic liver disease (MASLD): an RNA sequence database analysis and review. Biochem Pharmacol. 2024;116241. Available from: https://doi.org/10.1016/j.bcp.2024.116241
Zhang X, Gao T, Deng S, Shang L, Chen X, Chen K, et al. Fasting induces hepatic lipid accumulation by stimulating peroxisomal dicarboxylic acid oxidation. J Biol Chem. 2021;296:100622. Available from: https://doi.org/10.1016/j.jbc.2021.100622
Dietschy JM, Brown MS. Effect of alterations of the specific activity of the intracellular acetyl CoA pool on apparent rates of hepatic cholesterogenesis. J Lipid Res. 1974;15:508-516. Available from: https://pubmed.ncbi.nlm.nih.gov/4413018/
Passi S, Picardo M, Nazzaro-Porro M, Breathnach A, Confaloni AM, Serlupi-Crescenzi G. Antimitochondrial effect of saturated medium chain length (C8-C13) dicarboxylic acids. Biochem Pharmacol. 1984;33:103-108. Available from: https://doi.org/10.1016/0006-2952(84)90376-9
Tonsgard JH. Urinary dicarboxylic acids in Reye syndrome. J Pediatr. 1985;107:79-84. Available from: https://doi.org/10.1016/s0022-3476(85)80619-3
Rungratanawanich W, Ballway JW, Wang X, Won KJ, Hardwick JP, Song BJ. Post-translational modifications of histone and non-histone proteins in epigenetic regulation and translational applications in alcohol-associated liver disease: challenges and research opportunities. Pharmacol Ther. 2023;251:108547. Available from: https://doi.org/10.1016/j.pharmthera.2023.108547
Inouye M, Mio T, Sumino K. Dicarboxylic acids as markers of fatty acid peroxidation in diabetes. Atherosclerosis. 2000;148:197-202. Available from: https://doi.org/10.1016/s0021-9150(99)00263-4
Lu D, He A, Tan M, Mrad M, El Daibani A, Hu D, et al. Liver ACOX1 regulates levels of circulating lipids that promote metabolic health through adipose remodeling. Nat Commun. 2024;15:4214. Available from: https://www.nature.com/articles/s41467-024-48471-2
Abdelmegeed MA, Banerjee A, Jang S, Yoo SH, Yun JW, Gonzalez FJ, et al. CYP2E1 potentiates binge alcohol-induced gut leakiness, steatohepatitis, and apoptosis. Free Radic Biol Med. 2013;65:1238-1245. Available from: https://doi.org/10.1016/j.freeradbiomed.2013.09.009
Ruiz-Sala P, Pena-Quintana L. Biochemical markers for the diagnosis of mitochondrial fatty acid oxidation diseases. J Clin Med. 2021;10:4855. Available from: https://doi.org/10.3390/jcm10214855
Baldi S, Menicatti M, Nannini G, Niccolai E, Russo E, Ricci F, et al. Free fatty acids signature in human intestinal disorders: significant association between butyric acid and celiac disease. Nutrients. 2021;13:742. Available from: https://doi.org/10.3390/nu13030742
Mingrone G, Castagneto-Gissey L, Mace K. Use of dicarboxylic acids in type 2 diabetes. Br J Clin Pharmacol. 2013;75:671-676. Available from: https://doi.org/10.1111/j.1365-2125.2012.04177.x
Butera E, Termite F, Esposto G, Galasso L, Mignini I, Borriello R, et al. Exploring the role of bempedoic acid in metabolic dysfunction associated steatotic liver disease: actual evidence and future perspectives. Int J Mol Sci. 2024;25:6938. Available from: https://doi.org/10.3390/ijms25136938
Goetzman ES, Zhang BB, Zhang Y, Bharathi SS, Bons J, Rose J, et al. Dietary dicarboxylic acids provide a non-storable alternative fat source that protects mice against obesity. J Clin Invest. 2024;134:e174186. Available from: https://doi.org/10.1172/jci174186
Dias VC, Fung E, Snyder FF, Carter RJ, Parsons HG. Effects of medium-chain triglyceride feeding on energy balance in adult humans. Metabolism. 1990;39:887-891. Available from: https://doi.org/10.1016/0026-0495(90)90295-n
Wang H, Lu J, Chen X, Schwalbe M, Gorka JE, Mandel JA, et al. Acquired deficiency of peroxisomal dicarboxylic acid catabolism is a metabolic vulnerability in hepatoblastoma. J Biol Chem. 2021;296:100283. Available from: https://doi.org/10.1016/j.jbc.2021.100283
Gao H, Cao Y, Xia H, Zhu X, Jin Y. CYP4A11 is involved in the development of nonalcoholic fatty liver disease via ROS-induced lipid peroxidation and inflammation. Int J Mol Med. 2020;45:1121-1129. Available from: https://doi.org/10.3892/ijmm.2020.4479
Ni KD, Liu JY. The functions of cytochrome P450 omega-hydroxylases and the associated eicosanoids in inflammation-related diseases. Front Pharmacol. 2021;12:716801. Available from: https://doi.org/10.3389/fphar.2021.716801
Trefely S, Lovell CD, Snyder NW, Wellen KE. Compartmentalised acyl-CoA metabolism and roles in chromatin regulation. Mol Metab. 2020;38:100941. Available from: https://doi.org/10.1016/j.molmet.2020.01.005
Lu Y, Travnickova J, Badonyi M, Rambow F, Coates A, Khan Z, et al. ALDH1A3-acetaldehyde metabolism potentiates transcriptional heterogeneity in melanoma. Cell Rep. 2024;43:114406. Available from: https://doi.org/10.1016/j.celrep.2024.114406
Hardwick JPS, Rote P, Leahy C, Lee YK, Wolf AR, Diegisser D, et al. The CYP4/20-HETE/GPR75 axis in the progression of metabolic-associated steatosis liver disease (MASLD) to chronic liver disease. Front Physiol. 2024.
Gilani A, Agostinucci K, Hossain S, Pascale JV, Garcia V, Adebesin AM, et al. 20-HETE interferes with insulin signaling and contributes to obesity-driven insulin resistance. Prostaglandins Other Lipid Mediat. 2021;152:106485. Available from: https://doi.org/10.1016/j.prostaglandins.2020.106485
Li S, Wang C, Zhang X, Su W. Cytochrome P450 Omega-Hydroxylase 4a14 attenuates cholestatic liver fibrosis. Front Physiol. 2021;12:688259. Available from: https://doi.org/10.3389/fphys.2021.688259
Muller DN, Schmidt C, Barbosa-Sicard E, Wellner M, Gross V, Hercule H, et al. Mouse Cyp4a isoforms: enzymatic properties, gender- and strain-specific expression, and role in renal 20-hydroxyeicosatetraenoic acid formation. Biochem J. 2007;403:109-118. Available from: https://doi.org/10.1042/bj20061328
Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, Nebert DW. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes, and alternative-splice variants. Pharmacogenetics. 2004;14:1-18. Available from: https://doi.org/10.1097/00008571-200401000-00001
Song BJ. Ethanol-inducible cytochrome P450 (CYP2E1): biochemistry, molecular biology and clinical relevance: 1996 update. Alcohol Clin Exp Res. 1996;20:138A-146A. Available from: https://doi.org/10.1111/j.1530-0277.1996.tb01764.x
Song BJ, Abdelmegeed MA, Cho YE, Akbar M, Rhim JS, Song MK, et al. Contributing roles of CYP2E1 and other cytochrome P450 isoforms in alcohol-related tissue injury and carcinogenesis. Adv Exp Med Biol. 2019;1164:73-87. Available from: https://doi.org/10.1007/978-3-030-22254-3_6
Daly AK. Relevance of CYP2E1 to non-alcoholic fatty liver disease. Subcell Biochem. 2013;67:165-175. Available from: https://doi.org/10.1007/978-94-007-5881-0_5
Abdelmegeed MA, Banerjee A, Yoo SH, Jang S, Gonzalez FJ, Song BJ. Critical role of cytochrome P450 2E1 (CYP2E1) in the development of high fat-induced non-alcoholic steatohepatitis. J Hepatol. 2012;57:860-866. Available from: https://doi.org/10.1016/j.jhep.2012.05.019
Das SK, Vasudevan DM. Alcohol-induced oxidative stress. Life Sci. 2007;81:177-187. Available from: https://doi.org/10.1016/j.lfs.2007.05.005
Porubsky PR, Meneely KM, Scott EE. Structures of human cytochrome P-450 2E1: insights into the binding of inhibitors and both small molecular weight and fatty acid substrates. J Biol Chem. 2008;283:33698-707. Available from: https://doi.org/10.1074/jbc.m805999200
Dostalek M, Brooks JD, Hardy KD, Milne GL, Moore MM, Sharma S, et al. In vivo oxidative damage in rats is associated with barbiturate response but not other cytochrome P450 inducers. Mol Pharmacol. 2007;72:1419-1424. Available from: https://doi.org/10.1124/mol.107.040238
Bansal S, Liu CP, Sepuri NB, Anandatheerthavarada HK, Selvaraj V, Hoek J, et al. Mitochondria-targeted cytochrome P450 2E1 induces oxidative damage and augments alcohol-mediated oxidative stress. J Biol Chem. 2010;285:24609-24619. Available from: https://doi.org/10.1074/jbc.m110.121822
Massart J, Begriche K, Hartman JH, Fromenty B. Role of mitochondrial cytochrome P450 2E1 in healthy and diseased liver. Cells. 2022;11:288. Available from: https://doi.org/10.3390/cells11020288
Bai J, Cederbaum AI. Overexpression of CYP2E1 in mitochondria sensitizes HepG2 cells to the toxicity caused by depletion of glutathione. J Biol Chem. 2006;281:5128-5136. Available from: https://doi.org/10.1074/jbc.m510484200
Bansal S, Anandatheerthavarada HK, Prabu GK, Milne GL, Martin MV, Guengerich FP, et al. Human cytochrome P450 2E1 mutations that alter mitochondrial targeting efficiency and susceptibility to ethanol-induced toxicity in cellular models. J Biol Chem. 2013;288:12627-12644. Available from: https://doi.org/10.1074/jbc.m113.452367
Amet Y, Adas F, Nanji AA. Fatty acid omega- and (omega-1)-hydroxylation in experimental alcoholic liver disease: relationship to different dietary fatty acids. Alcohol Clin Exp Res. 1998;22:1493-1500. Available from: https://pubmed.ncbi.nlm.nih.gov/9802534/
Amet Y, Berthou F, Baird S, Dreano Y, Bail JP, Menez JF. Validation of the (omega-1)-hydroxylation of lauric acid as an in vitro substrate probe for human liver CYP2E1. Biochem Pharmacol. 1995;50:1775-1782. Available from: https://doi.org/10.1016/0006-2952(95)02040-3
Bjorkhem I. On the role of alcohol dehydrogenase in omega-oxidation of fatty acids. Eur J Biochem. 1972;30:441-451. Available from: https://doi.org/10.1111/j.1432-1033.1972.tb02116.x
Keller MA, Watschinger K, Golderer G, Maglione M, Sarg B, Lindner HH, et al. Monitoring of fatty aldehyde dehydrogenase by formation of pyrenedecanoic acid from pyrenedecanal. J Lipid Res. 2010;51:1554-1559. Available from: https://doi.org/10.1194/jlr.d002220
Zhou J, Yin Y, Yang Y, Peng D, Wei J, Yin G, et al. Knockdown of miR-423-5p simultaneously upgrades the eNOS and VEGFa pathways in ADSCs and improves erectile function in diabetic rats. J Cell Mol Med. 2021;25:9796-9804. Available from: https://doi.org/10.1111/jcmm.16927
Deleve LD. Sinusoidal obstruction syndrome. Gastroenterol Hepatol (N Y). 2008;4:101-103. Available from: Available from: https://pubmed.ncbi.nlm.nih.gov/21904484/
Funyu J, Mochida S, Inao M, Matsui A, Fujiwara K. VEGF can act as vascular permeability factor in the hepatic sinusoids through upregulation of porosity of endothelial cells. Biochem Biophys Res Commun. 2001;280:481-485. Available from: https://doi.org/10.1006/bbrc.2000.4148
Iwakiri Y, Trebicka J. Portal hypertension in cirrhosis: pathophysiological mechanisms and therapy. JHEP Rep. 2021;3:100316. Available from: https://doi.org/10.1016/j.jhepr.2021.100316
Scroggins BT, Robzyk K, Wang D, Marcu MG, Tsutsumi S, Beebe K, et al. An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol Cell. 2007;25:151-159. Available from: https://doi.org/10.1016/j.molcel.2006.12.008
Schierwagen R, Dietrich P, Klein S, Uschner FE, Ortiz C, Tyc O, et al. beta-Arrestin2 is increased in liver fibrosis in humans and rodents. Proc Natl Acad Sci U S A. 2020;117:27082-27084. Available from: https://doi.org/10.1073/pnas.2014337117
Attal N, Marrero E, Thompson KJ, McKillop IH. Cytochrome P450 2E1-dependent hepatic ethanol metabolism induces fatty acid-binding protein 4 and steatosis. Alcohol Clin Exp Res. 2022;46:928-940. Available from: https://doi.org/10.1111/acer.14828
Gao N, Chen J, Li Y, Ding Y, Han Z, Xu H, et al. The CYP2E1 inhibitor Q11 ameliorates LPS-induced sepsis in mice by suppressing oxidative stress and NLRP3 activation. Biochem Pharmacol. 2023;214:115638. Available from: https://doi.org/10.1016/j.bcp.2023.115638
Nagappan A, Jung DY, Kim JH, Lee H, Jung MH. Gomisin N alleviates ethanol-induced liver injury through ameliorating lipid metabolism and oxidative stress. Int J Mol Sci. 2018;19:2601. Available from: https://doi.org/10.3390/ijms19092601
Zong H, Armoni M, Harel C, Karnieli E, Pessin JE. Cytochrome P-450 CYP2E1 knockout mice are protected against high-fat diet-induced obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2012;302:E532-539. Available from: https://doi.org/10.1152/ajpendo.00258.2011
Woodcroft KJ, Hafner MS, Novak RF. Insulin signaling in the transcriptional and posttranscriptional regulation of CYP2E1 expression. Hepatology. 2002;35:263-273. Available from: https://doi.org/10.1053/jhep.2002.30691
Kathirvel E, Morgan K, French SW, Morgan TR. Overexpression of liver-specific cytochrome P4502E1 impairs hepatic insulin signaling in a transgenic mouse model of nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2009;21:973-983. Available from: https://doi.org/10.1097/meg.0b013e328328f461
Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest. 2000;105:1067-1075. Available from: https://doi.org/10.1172/jci8814
Park EC, Kim SI, Hong Y, Hwang JW, Cho GS, Cha HN, et al. Inhibition of CYP4A reduces hepatic endoplasmic reticulum stress and features of diabetes in mice. Gastroenterology. 2014;147:860-869. Available from: https://doi.org/10.1053/j.gastro.2014.06.039
Gilani A, Pandey V, Garcia V, Agostinucci K, Singh SP, Schragenheim J, et al. High-fat diet-induced obesity and insulin resistance in CYP4a14(-/-) mice is mediated by 20-HETE. Am J Physiol Regul Integr Comp Physiol. 2018;315:R934-944. Available from: https://doi.org/10.1152/ajpregu.00125.2018
Gong P, Cederbaum AI. Transcription factor Nrf2 protects HepG2 cells against CYP2E1 plus arachidonic acid-dependent toxicity. J Biol Chem. 2006;281:14573-14579. Available from: https://doi.org/10.1074/jbc.m600613200
Tice AL, Steiner JL. Binge alcohol induces NRF2-related antioxidant response in the skeletal muscle of female mice. Biochem Biophys Res Commun. 2024;714:149968. Available from: https://doi.org/10.1016/j.bbrc.2024.149968
Ma Q. Role of Nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol. 2013;53:401-426. Available from: https://doi.org/10.1146/annurev-pharmtox-011112-140320
Meakin PJ, Chowdhry S, Sharma RS, Ashford FB, Walsh SV, McCrimmon RJ, et al. Susceptibility of Nrf2-null mice to steatohepatitis and cirrhosis upon consumption of a high-fat diet is associated with oxidative stress, perturbation of the unfolded protein response, and disturbance in the expression of metabolic enzymes but not with insulin resistance. Mol Cell Biol. 2014;34:3305-3320. Available from: https://doi.org/10.1128/mcb.00677-14
Tunaru S, Bonnavion R, Brandenburger I, Preussner J, Thomas D, Scholich K, et al. 20-HETE promotes glucose-stimulated insulin secretion in an autocrine manner through FFAR1. Nat Commun. 2018;9:177. Available from: https://doi.org/10.1038/s41467-017-02539-4
Wu CC, Gupta T, Garcia V, Ding Y, Schwartzman ML. 20-HETE and blood pressure regulation: clinical implications. Cardiol Rev. 2014;22:1-12. Available from: https://doi.org/10.1097/crd.0b013e3182961659
Froogh G, Garcia V, Laniado Schwartzman M. The CYP/20-HETE/GPR75 axis in hypertension. Adv Pharmacol. 2022;94:1-25. Available from: https://doi.org/10.1016/bs.apha.2022.02.003
Helal SA, Gerges SH, El-Kadi AOS. Enantioselectivity in some physiological and pathophysiological roles of hydroxyeicosatetraenoic acids. Drug Metab Rev. 2024;56:31-45. Available from: https://doi.org/10.1080/03602532.2023.2284110
Panigrahy D, Kaipainen A, Greene ER, Huang S. Cytochrome P450-derived eicosanoids: the neglected pathway in cancer. Cancer Metastasis Rev. 2010;29:723-735. Available from: https://doi.org/10.1007/s10555-010-9264-x
Schuck RN, Theken KN, Edin ML, Caughey M, Bass A, Ellis K, et al. Cytochrome P450-derived eicosanoids and vascular dysfunction in coronary artery disease patients. Atherosclerosis. 2013;227:442-448. Available from: https://doi.org/10.1016/j.atherosclerosis.2013.01.034
Dakarapu R, Errabelli R, Manthati VL, Adebesin AM, Barma DK, Barma D, et al. 19-Hydroxyeicosatetraenoic acid analogs: Antagonism of 20-hydroxyeicosatetraenoic acid-induced vascular sensitization and hypertension. Bioorg Med Chem Lett. 2019;29:126616. Available from: https://doi.org/10.1016/j.bmcl.2019.08.020
Shoieb SM, El-Sherbeni AA, El-Kadi AOS. Subterminal hydroxy eicosatetraenoic acids: Crucial lipid mediators in normal physiology and disease states. Chem Biol Interact. 2019;299:140-150. Available from: https://doi.org/10.1016/j.cbi.2018.12.004
Powell PK, Wolf I, Lasker JM. Identification of CYP4A11 as the major lauric acid omega-hydroxylase in human liver microsomes. Arch Biochem Biophys. 1996;335:219-226. Available from: https://doi.org/10.1006/abbi.1996.0501
Porubsky PR, Battaile KP, Scott EE. Human cytochrome P450 2E1 structures with fatty acid analogs reveal a previously unobserved binding mode. J Biol Chem. 2010;285:22282-22290. Available from: https://doi.org/10.1074/jbc.m110.109017
Pascale JV, Park EJ, Adebesin AM, Falck JR, Schwartzman ML, Garcia V. Uncovering the signalling, structure, and function of the 20-HETE-GPR75 pairing: Identifying the chemokine CCL5 as a negative regulator of GPR75. Br J Pharmacol. 2021;178:3813-3828. Available from: https://doi.org/10.1111/bph.15525
Escalante B, Falck JR, Yadagiri P, Sun LM, Laniado-Schwartzman M. 19(S)-hydroxyeicosatetraenoic acid is a potent stimulator of renal Na+-K+-ATPase. Biochem Biophys Res Commun. 1988;152:1269-1274. Available from: https://doi.org/10.1016/s0006-291x(88)80422-4
Escalante B, Sessa WC, Falck JR, Yadagiri P, Schwartzman ML. Cytochrome P450-dependent arachidonic acid metabolites, 19- and 20-hydroxyeicosatetraenoic acids, enhance sodium-potassium ATPase activity in vascular smooth muscle. J Cardiovasc Pharmacol. 1990;16:438-443. Available from: https://doi.org/10.1097/00005344-199009000-00013
Hammoutene A, Rautou PE. Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease. J Hepatol. 2019;70:1278-1291. Available from: https://doi.org/10.1016/j.jhep.2019.02.012
Ruan B, Duan JL, Xu H, Tao KS, Han H, Dou GR, et al. Capillarized liver sinusoidal endothelial cells undergo partial endothelial-mesenchymal transition to actively deposit sinusoidal ECM in liver fibrosis. Front Cell Dev Biol. 2021;9:671081. Available from: https://doi.org/10.3389/fcell.2021.671081
Leung TM, Tipoe GL, Liong EC, Lau TY, Fung ML, Nanji AA. Endothelial nitric oxide synthase is a critical factor in experimental liver fibrosis. Int J Exp Pathol. 2008;89:241-250. Available from: https://doi.org/10.1111/j.1365-2613.2008.00590.x
Hartl L, Rumpf B, Domenig O, Simbrunner B, Paternostro R, Jachs M, et al. The systemic and hepatic alternative renin-angiotensin system is activated in liver cirrhosis, linked to endothelial dysfunction and inflammation. Sci Rep. 2023;13:953. Available from: https://doi.org/10.1038/s41598-023-28239-2
Bataller R, Nicolas JM, Gines P, Gorbig MN, Garcia-Ramallo E, Lario S, et al. Contraction of human hepatic stellate cells activated in culture: a role for voltage-operated calcium channels. J Hepatol. 1998;29:398-408. Available from: https://doi.org/10.1016/s0168-8278(98)80057-3
Bataller R, Gines P, Nicolas JM, Gorbig MN, Garcia-Ramallo E, Gasull X, et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology. 2000;118:1149-1156. Available from: https://doi.org/10.1016/s0016-5085(00)70368-4
Sacerdoti D, Balazy M, Angeli P, Gatta A, McGiff JC. Eicosanoid excretion in hepatic cirrhosis. Predominance of 20-HETE. J Clin Invest. 1997;100:1264-1270. Available from: https://doi.org/10.1172/jci119640
Sacerdoti D, Jiang H, Gaiani S, McGiff JC, Gatta A, Bolognesi M. 11,12-EET increases porto-sinusoidal resistance and may play a role in endothelial dysfunction of portal hypertension. Prostaglandins Other Lipid Mediat. 2011;96:72-75. Available from: https://doi.org/10.1016/j.prostaglandins.2011.08.002
Sacerdoti D, Pesce P, Di Pascoli M, Brocco S, Cecchetto L, Bolognesi M. Arachidonic acid metabolites and endothelial dysfunction of portal hypertension. Prostaglandins Other Lipid Mediat. 2015;120:80-90. Available from: https://doi.org/10.1016/j.prostaglandins.2015.05.008
Schwartzman ML, Falck JR, Yadagiri P, Escalante B. Metabolism of 20-hydroxyeicosatetraenoic acid by cyclooxygenase. Formation and identification of novel endothelium-dependent vasoconstrictor metabolites. J Biol Chem. 1989;264:11658-11662. Available from: https://pubmed.ncbi.nlm.nih.gov/2501294/
Zhang Y, Hoda MN, Zheng X, Li W, Luo P, Maddipati KR, et al. Combined therapy with COX-2 inhibitor and 20-HETE inhibitor reduces colon tumor growth and the adverse effects of ischemic stroke associated with COX-2 inhibition. Am J Physiol Regul Integr Comp Physiol. 2014;307:R693-703. Available from: https://doi.org/10.1152/ajpregu.00422.2013
Liu JY, Li N, Yang J, Li N, Qiu H, Ai D, et al. Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events. Proc Natl Acad Sci U S A. 2010;107:17017-17022. Available from: https://doi.org/10.1073/pnas.1011278107
Sacerdoti D, Gatta A, McGiff JC. Role of cytochrome P450-dependent arachidonic acid metabolites in liver physiology and pathophysiology. Prostaglandins Other Lipid Mediat. 2003;72:51-71. Available from: https://doi.org/10.1016/s1098-8823(03)00077-7
Kim DH, Puri N, Sodhi K, Falck JR, Abraham NG, Shapiro J, et al. Cyclooxygenase-2 dependent metabolism of 20-HETE increases adiposity and adipocyte enlargement in mesenchymal stem cell-derived adipocytes. J Lipid Res. 2013;54:786-793. Available from: https://doi.org/10.1194/jlr.m033894
Alexanian A, Miller B, Roman RJ, Sorokin A. 20-HETE-producing enzymes are up-regulated in human cancers. Cancer Genomics Proteomics. 2012;9:163-169. Available from: https://pubmed.ncbi.nlm.nih.gov/22798501/
Gu W, Zeng D, Zhang C. Discovering the effect of combination of celecoxib and sorafenib on hepatocellular carcinoma. Discov Oncol. 2024;15:321. Available from: https://doi.org/10.1007/s12672-024-01203-w
Morisaki T, Umebayashi M, Kiyota A, Koya N, Tanaka H, Onishi H, et al. Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro. Anticancer Res. 2013;33:1387-1395. Available from: https://pubmed.ncbi.nlm.nih.gov/23564777/
Cui J, Guo YH, Zhang HY, Jiang LL, Ma JQ, Wang WJ, et al. Cyclooxygenase-2 inhibitor is a robust enhancer of anticancer agents against hepatocellular carcinoma multicellular spheroids. Onco Targets Ther. 2014;7:353-363. Available from: https://doi.org/10.2147/ott.s56115
Hsu MH, Savas U, Griffin KJ, Johnson EF. Regulation of human cytochrome P450 4F2 expression by sterol regulatory element-binding protein and lovastatin. J Biol Chem. 2007;282:5225-5236. Available from: Available from: https://doi.org/10.1074/jbc.m608176200
Poloyac SM, Tortorici MA, Przychodzin DI, Reynolds RB, Xie W, Frye RF, et al. The effect of isoniazid on CYP2E1- and CYP4A-mediated hydroxylation of arachidonic acid in the rat liver and kidney. Drug Metab Dispos. 2004;32:727-733. Available from: https://doi.org/10.1124/dmd.32.7.727
Zhang Q, Wu S, Chen Q, Zhang Y, Zhang C, Yin R, et al. Reducing oxidative stress-mediated alcoholic liver injury by multiplexed RNAi of Cyp2e1, Cyp4a10, and Cyp4a14. Biomedicines. 2024;12:1505. Available from: https://doi.org/10.3390/biomedicines12071505
Ma X, Baraona E, Lieber CS. Alcohol consumption enhances fatty acid omega-oxidation, with a greater increase in male than in female rats. Hepatology. 1993;18:1247-1253. Available from: https://pubmed.ncbi.nlm.nih.gov/8225232/
Polavarapu R, Spitz DR, Sim JE, Follansbee MH, Oberley LW, Rahemtulla A, et al. Increased lipid peroxidation and impaired antioxidant enzyme function is associated with pathological liver injury in experimental alcoholic liver disease in rats fed diets high in corn oil and fish oil. Hepatology. 1998;27:1317-1323. Available from: https://doi.org/10.1002/hep.510270518
Malnick SDH, Alin P, Somin M, Neuman MG. Fatty liver disease—alcoholic and non-alcoholic: similar but different. Int J Mol Sci. 2022;23:1626. Available from: https://doi.org/10.3390/ijms232416226
Orellana M, Rodrigo R, Varela N, Araya J, Poniachik J, Csendes A, et al. Relationship between in vivo chlorzoxazone hydroxylation, hepatic cytochrome P450 2E1 content and liver injury in obese non-alcoholic fatty liver disease patients. Hepatol Res. 2006;34:57-63. Available from: https://doi.org/10.1016/j.hepres.2005.10.001
Michaels S, Wang MZ. The revised human liver cytochrome P450 "Pie": absolute protein quantification of CYP4F and CYP3A enzymes using targeted quantitative proteomics. Drug Metab Dispos. 2014;42:1241-1251. Available from: https://doi.org/10.1124/dmd.114.058040
Northup PG, Argo CK, Shah N, Caldwell SH. Hypercoagulation and thrombophilia in nonalcoholic fatty liver disease: mechanisms, human evidence, therapeutic implications, and preventive implications. Semin Liver Dis. 2012;32:39-48. Available from: https://doi.org/10.1055/s-0032-1306425
Anstee QM, Wright M, Goldin R, Thursz MR. Parenchymal extinction: coagulation and hepatic fibrogenesis. Clin Liver Dis. 2009;13:117-126. Available from: https://doi.org/10.1016/j.cld.2008.09.013
Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in the development of parenchymal extinction and portal hypertension. Hepatology. 1995;21:1238-1247. Available from: https://pubmed.ncbi.nlm.nih.gov/7737629/